While these data require confirmation with proteomic and metabolomic approaches, the overlapping expression of IL4i1 and IDO1 in the TME raises a significant issue for cancer therapy approaches that target either IDO1 or IL4i1: namely, that both enzymes are generating a potentially similar aromatic amino acid metabolic milieu that may be redundant. The gene discussed is IL4I1; the disease is cancer.